How long does B7-33 take to work?
In the first week of B7-33, no documented human user reports of acute effects. Around week 4, pre-clinical models show anti-fibrotic markers shifting around here. By week 8, no long term human data exists. Response varies between people, this is the commonly reported pattern, not a guarantee.
Week by week
- Week 1: No documented human user reports of acute effects.
- Week 4: Pre-clinical models show anti-fibrotic markers shifting around here.
- Week 8: No long term human data exists.
References
- B7-33, single-chain peptide derivative of relaxin retains anti-fibrotic activity without hemodynamic effects — Hossain MA et al., Chem Sci, 2016
- B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin) — Marshall SA, O'Sullivan K, Ng HH, et al., European Journal of Pharmacology, 2017
- Single chain peptide agonists of relaxin receptors — Praveen P, Kocan M, Valkovic A, et al., Molecular and Cellular Endocrinology, 2019
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on B7-33
Last updated 2026-06-06.